FDA Commissioner Says Funding Imperils Agency Mission, Modernization
Executive Summary
FDA's modernization efforts are essential for the agency to succeed as a regulatory organization in the future, but there will be no "quick fix," FDA Commissioner Andrew von Eschenbach said March 26 in an address to the Food and Drug Law Institute's annual conference
You may also be interested in...
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
Reagan-Udall Foundation Approaches The Starting Line; Next Step Is Funding
The FDA Amendments Act, which reauthorized the user fee program and gave FDA broad new powers to ensure drug safety, has given the agency an abundance of oversight functions to organize, but also has provided the agency an outside partner: The Reagan-Udall Foundation